Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease

RC Ungaro, A Yarur, J Jossen, BL Phan… - Journal of Crohn's …, 2019 - academic.oup.com
Abstract Background and Aims Vedolizumab is an anti-α4β7 biologic approved for ulcerative
colitis [UC] and Crohn's disease [CD]. We aimed to examine the association of maintenance …

Combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab

AJ Yarur, D McGovern, MT Abreu, A Cheifetz… - Clinical …, 2023 - Elsevier
Abstract Background and Aims The aim of this study was to assess how 6-thioguanine
nucleotide (6-TGN) levels and use of oral methotrexate relate to the pharmacokinetics of …

Vedolizumab concentrations are associated with long-term endoscopic remission in patients with inflammatory bowel diseases

AJ Yarur, A Bruss, S Naik, P Beniwal-Patel… - Digestive diseases and …, 2019 - Springer
Background The aim of this study was to assess the relationship of serum vedolizumab
concentrations (SVC) during induction and endoscopic remission in patients with …

Patients with inflammatory bowel diseases and higher visceral adipose tissue burden may benefit from higher infliximab concentrations to achieve remission

AJ Yarur, MT Abreu, P Deepak… - Official journal of the …, 2022 - journals.lww.com
METHODS: We conducted a prospective cross-sectional study of patients with IBD receiving
maintenance infliximab therapy. We measured baseline body composition parameters …

DOP020 Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with …

A Yarur, A Bruss, A Jain, V Kondragunta2… - Journal of Crohn's …, 2017 - academic.oup.com
Background: Vedolizumab (VDZ) has been found to be efficacious in the treatment of
Crohn's disease (CD) and ulcerative colitis (UC), even though some patients present with …

Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases …

AJ Yarur, A Bruss, A Moosreiner, P Beniwal-Patel… - Gastroenterology, 2023 - Elsevier
Background & Aims We sought to assess the association between intra-abdominal visceral
adipose tissue (IA-VAT) and response to 3 different biologic drugs in patients with …

P552 Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel …

A Yarur, R Ungaro, A Jain, L Nunex… - Journal of Crohn's …, 2022 - academic.oup.com
Background Ustekinumab (UST) is currently approved for the treatment of Crohn's disease
(CD) and ulcerative colitis (UC). However, a significant number of patients either partially …

S967 The Correlation Between Visceral Abdominal and Total Adipose Tissue With Metabolic Risk Factors in Patients With Inflammatory Bowel Diseases

A Yarur, L Nunez, BE Berens… - Official journal of the …, 2021 - journals.lww.com
Methods: We performed a prospective cross-sectional study included patients with IBD.
Patients on any pharmacologic therapy known to affect lipoprotein levels were excluded …

S171 The Association Between Stool Shedding of SARS-Cov-2, Microbiome Diversity and Intestinal Inflammation

A Yarur, A Bruss, BE Berens, L Nunez… - Official journal of the …, 2022 - journals.lww.com
Methods: This was a prospective cohort study that included outpatients that presented with
symptoms of COVID-19 and were tested using a nasopharyngeal PCR test (NPT). Two …

[HTML][HTML] Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease

S Sekhri, B Rao, A Mohananey… - BMJ Open …, 2021 - bmjopengastro.bmj.com
Background Infliximab is an efficacious therapy for inflammatory bowel disease and may
play a role in management of some extraintestinal manifestations. While higher trough levels …